LITFULO

This brand name is authorized in Austria, Estonia, France, Croatia, Ireland, Italy, Lithuania, United Kingdom, United States

Active ingredients

The drug LITFULO contains one active pharmaceutical ingredient (API):

1 Ritlecitinib UNII EAG4T1459K - RITLECITINIB TOSYLATE

Ritlecitinib irreversibly and selectively inhibits Janus kinase (JAK) 3 and the tyrosine kinase expressed in hepatocellular carcinoma (TEC) family by blocking the adenosine triphosphate (ATP) binding site. JAK3 and TEC family mediated signalling pathways are both involved in alopecia areata pathogenesis, although complete pathophysiology is still not understood. Read about Ritlecitinib

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
LITFULO Hard capsule	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L04AF08		L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AF Janus-associated kinase (JAK) inhibitors
Discover more medicines within L04AF08

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 3045844, 3045855, 3045866
Country: FR	Base de données publique des médicaments	Identifier(s): 62624259
Country: IT	Agenzia del Farmaco	Identifier(s): 050899018, 050899020, 050899032
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1097725, 1097726, 1097727
Country: US	FDA, National Drug Code	Identifier(s): 0069-0334, 63539-334